Back to News
May 7, 2026 4:00 PM

ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum

ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading lower by 11.46% on Thursday as the company recently reported record first quarter 2026 results, which included significant revenue growth.

• ImmunityBio stock is among today’s weakest performers. Why is IBRX stock falling?

ImmunityBio (IBRX) Q1 Results Drive Revenue Growth Focus

The cancer drug company reported a first-quarter loss of 62 cents, missing the consensus loss of seven cents. Adjusted loss was eight cents.

Sales reached $44.21 million, up from $16.52 million a year ago, beating the consensus of $43.07 million, representing an 168% year-over-year increase.

Product revenue increased $27.7 million year over year due to increased net trade sales of Anktiva as a result of ongoing commercial activities.

The company said 168% increase in Anktiva unit sales volume.

ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check